Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Public ClinicalTrials.gov record NCT06787612. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multi-Arm Phase 2 Platform Study of Ubamatamab (REGN4018; MUC16×CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab, REGN10597 and a standard chemotherapy drug, pegylated liposomal doxorubicin \[PLD\]), referred to as "combination drugs'. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug and its experimental combinations * How much study drug and fianlimab is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) and its combinations
Study identification
- NCT ID
- NCT06787612
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 297 participants
Conditions and interventions
Interventions
- Ubamatamab Drug
- Bevacizumab Drug
- Cemiplimab Drug
- Fianlimab Drug
- PLD Drug
- Sarilumab Drug
- REGN10597 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 27, 2025
- Primary completion
- Jun 29, 2028
- Completion
- Jun 29, 2028
- Last update posted
- Aug 11, 2026
2025 – 2028
United States locations
- U.S. sites
- 21
- U.S. states
- 15
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Alabama at Birmingham | Birmingham | Alabama | 35233 | Recruiting |
| UC San Diego Health | La Jolla | California | 92037 | Recruiting |
| Cedars Sinai Medical Center | Los Angeles | California | 90048 | Recruiting |
| Mayo Clinic Jacksonville | Jacksonville | Florida | 32224 | Recruiting |
| University of Miami Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | Recruiting |
| Advent Health Cancer Institute | Orlando | Florida | 32804 | Recruiting |
| Tampa General Hospital Cancer Institute | Tampa | Florida | 33606 | Recruiting |
| University of Chicago | Chicago | Illinois | 60637 | Recruiting |
| The University of Kansas Cancer Center | Westwood | Kansas | 66205 | Recruiting |
| Norton Cancer Institute, St. Matthews Clinic | Louisville | Kentucky | 40207 | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Recruiting |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | Recruiting |
| The Ohio State University Comprehensive Cancer Center | Hilliard | Ohio | 43026 | Recruiting |
| Providence Cancer Institute | Portland | Oregon | 97213 | Recruiting |
| University of Pittsburgh Medical Center, Magee-Womens Hospital | Pittsburgh | Pennsylvania | 15213 | Recruiting |
| West Penn Hospital of Allegheny Health Network | Pittsburgh | Pennsylvania | 15224 | Recruiting |
| Avera Cancer Institute Sioux Falls | Sioux Falls | South Dakota | 57105 | Recruiting |
| UT Southwestern Medical Center | Dallas | Texas | 75390 | Recruiting |
| Swedish Cancer Institute | Seattle | Washington | 98104 | Recruiting |
| University of Wisconsin | Madison | Wisconsin | 53792 | Recruiting |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06787612, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 11, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06787612 live on ClinicalTrials.gov.